9.4-T MRI monitoring of early MASH progression and therapeutic response in a prefibrotic mouse model
Authors:
Open Access
- 6 May 2026
- journal article
- Published by Springer Nature in European Radiology Experimental
- Vol. 10 (1)
Abstract
Objective: Early intervention in metabolic dysfunction-associated steatohepatitis (MASH) is critical to halt disease progression. However, noninvasive tools for monitoring early-stage MASH and therapeutic efficacy in preclinical models remain limited, impeding preclinical drug development. This study establishes an integrated approach using multiparametric magnetic resonance imaging (MRI) at 9.4 T to dynamically track disease development and drug response in a prefibrotic MASH mouse model. Materials and methods: Mice were fed a high-fat and high-cholesterol diet (HFHCD) for 16 weeks to induce early MASH without fibrosis and treated with the anti-MASH drug semaglutide for 8 weeks after modeling. Longitudinal MRI assessments—including proton density fat fraction (PDFF), 1 H magnetic resonance spectroscopy (MRS), T 2 mapping, and diffusion-weighted imaging (DWI)—were performed every 4 weeks and correlated with histopathology. Results: Histology confirmed early MASH after 16 weeks, without fibrosis. All MRI parameters strongly correlated with histopathological scores. HFHCD feeding led to significant changes: PDFF, MRS-derived liver fat content (LFC), and T 2 values increased by 6.8-, 5.2-, and 2.5-fold, respectively, while apparent diffusion coefficient (ADC) decreased by 30% ( p < 0.001). T 2 and ADC also correlated with MRS-quantified saturated fatty acids. Semaglutide treatment effectively reversed these changes: PDFF decreased by 73%, LFC by 62%, T 2 by 46% ( p < 0.001), and ADC increased 1.4-fold ( p = 0.017) compared to the vehicle group. Conclusion: This work demonstrates multiparametric MRI as a powerful noninvasive platform for monitoring early MASH dynamics and treatment response. By enabling longitudinal assessment in a prefibrotic model, this approach accelerates translational research in MASH diagnosis and drug development. Relevance statement: The established multiparametric MRI evaluation system provides a valuable noninvasive monitoring platform for preclinical early-stage MASH research, demonstrating significant potential to accelerate the translational progress in MASH diagnosis and drug development. Key Points: A novel prefibrotic MASH model was established to assess early-stage MASH progression. Multiparametric MRI at 9.4 T enables noninvasive, longitudinal monitoring of early MASH. Semaglutide-induced improvement in steatosis and inflammation can be monitored by multiparametric MRI. GraphicalKeywords
Funding Information
- National Key Research and Development Program of China (No. 2022YFC3400502)
- National Key Research and Development Program of China (No. 2022YFC3400500)
- Beijing Life Science Academy (No. 2024100CA0060)
- Beijing Life Science Academy (2023000CA0070)
- Plans for Major Anhui Provincial Science & Technology Projects (No. 202303a07020004)
- National Facility for Translational Medicine
This publication has 40 references indexed in Scilit:
- Multicenter Validation of Association Between Decline in MRI‐PDFF and Histologic Response in NASHHepatology, 2020
- Quantitative 1H MRI and MRS of fatty acid compositionMagnetic Resonance in Medicine, 2020
- Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trialsHepatology, 2013
- Determination of reliability criteria for liver stiffness evaluation by transient elastographyHepatology, 2012
- Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patientsHepatology, 2012
- Measurement of liver T1 and T2 relaxation times in an experimental mouse model of liver fibrosisJournal of Magnetic Resonance Imaging, 2012
- Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD)Hepatology, 2009
- T1, T2 relaxation and magnetization transfer in tissue at 3TMagnetic Resonance in Medicine, 2005
- Apparent diffusion coefficient measurements with diffusion‐weighted magnetic resonance imaging for evaluation of hepatic fibrosisJournal of Magnetic Resonance Imaging, 2005
- Detection of liver fibrosis with magnetic cross‐relaxationMagnetic Resonance in Medicine, 1994